Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients.

Arrobas A, Barbosa MP, Rabiais S, Vandewalle B, Félix J.

Open source

DOI: 10.1016/j.pulmoe.2020.03.001
Published: 2020-04-01
Container: Pulmonology
Publisher: Not recorded
Open access: no

Credibility signals

uncertain Score 51/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.pulmoe.2020.03.001,
  title = {Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients.},
  author = {Arrobas A and  Barbosa MP and  Rabiais S and  Vandewalle B and  Félix J.},
  year = {2021},
  journal = {Pulmonology},
  doi = {10.1016/j.pulmoe.2020.03.001},
  url = {https://doi.org/10.1016/j.pulmoe.2020.03.001}
}

RIS

TY  - JOUR
TI  - Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients.
AU  - Arrobas A
AU  -  Barbosa MP
AU  -  Rabiais S
AU  -  Vandewalle B
AU  -  Félix J.
PY  - 2021
JO  - Pulmonology
DO  - 10.1016/j.pulmoe.2020.03.001
UR  - https://doi.org/10.1016/j.pulmoe.2020.03.001
ER  -

APA

A, A., MP, B., S, R., B, V., & J., F. (2021). Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients.. Pulmonology. https://doi.org/10.1016/j.pulmoe.2020.03.001

Source records

europe-pmc · retrieved 2026-09-27T07:49:54.200Z
doaj · retrieved 2026-09-27T07:49:54.219Z
doaj · retrieved 2026-09-27T07:49:54.219Z